The Vall d’Hebron Initiative for Parkinson (VHIP) cohort: a prospective, longitudinal, and observational study enrolling de novo Parkinson’s disease patients for biomarker identification and validation

作者：Daniela Samaniego, Silvia Enríquez-Calzada, L. Domingo, M. Armengol, M. Camprodón, Laura Melgarejo, Mercedes Arrúe-Gonzalo, Maria Miret-Milian, V. González, S. Belmonte, S. Lucas-Del-Pozo, Helena Xicoy, Anna Carrasco, Jordi Riera, E. Pradas, Pablo Castillo-Sánchez, Marta Montpeyo, David Montpeyó, M. A. Zapata, Miquel Vila, Marta Martinez-Vicente, A. Laguna, J. Hernández-Vara · 发表于：Frontiers in Aging Neuroscience · 年份：2026 · DOI：10.3389/fnagi.2026.1858685 · 研究领域：Medicine

Background Parkinson’s disease (PD) is a progressive neurodegenerative disorder causing a variety of motor and non-motor symptoms. To date, no disease modifying treatment exists, and diagnosis is based on the manifestation of the clinical motor symptoms, which occurs when the neurodegenerative process is already advanced. Studies designed to find diagnostic/prognostic biomarkers and pathophysiological pathways involved in disease onset/progression are needed. Objective To describe the study protocol of the Vall d’Hebron Initiative for Parkinson (VHIP) Cohort, a prospective and longitudinal observational cohort study aimed at deeply phenotyping de novo PD patients, including carriers of PD-linked mutations. We anticipate this initiative will contribute to identifying biomarkers for PD risk, diagnosis, and prognosis, as well as to stratify disease subtypes and increase our understanding of pathophysiology at early disease stages. Methods/Design Subjects are prospectively recruited by movement disorder specialists at the Vall d’Hebron University Hospital (VHUH). To date, the study cohort includes 174 subjects—consisting of 117 patients with de novo Parkinson’s disease, 17 individuals with REM sleep behavior disorder (RBD), and 33 healthy controls—and recruitment is still ongoing. After informed consent, subjects are evaluated in detail to primarily assess objectives within four major domains of PD: motor, cognitive-affective, autonomic function, and vision. This includes first a...